<DOC>
	<DOCNO>NCT02481414</DOCNO>
	<brief_summary>This Phase II study evaluate efficacy safety human papilloma virus ( HPV ) therapeutic vaccine call PepCan ( HPV 16 E6 peptide combine Candida skin test reagent call Candin® ) adult female 12 month time period . As result Phase I trial demonstrate efficacy non-16 HPV type , Candin alone also test . Therefore , two treatment arm : ( 1 ) PepCan ( 2 ) Candin . Subjects find eligible vaccination randomize double-blinded fashion 1:1 ratio . Each participant receive injection four time three week injection . Clinical virological response assess 6 12 month . Safety assess time enrollment 12 Month Visit . Immunological assessment make 4 time point ( prevaccination , 2 injection , 6 month 4 injection 12 month 4 vaccination ) .</brief_summary>
	<brief_title>A Clinical Trial PepCan Two Therapy Arms Treating Cervical High-Grade Squamous Intraepithelial Lesions</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Squamous Intraepithelial Lesions Cervix</mesh_term>
	<mesh_term>Uterine Cervical Dysplasia</mesh_term>
	<criteria>Aged 1850 year Had recent ( ≤ 60 day ) Pap smear result consistent high grade squamous intraepithelial lesion ( HSIL ) `` rule HSIL '' HSIL colposcopyguided biopsy Untreated HSIL `` Can rule HSIL '' Able provide inform consent Willingness able comply requirement protocol good command English language History disease treatment cause immunosuppression ( e.g. , cancer , human immunodeficiency virus , organ transplant , autoimmune disease ) Being pregnant attempt pregnant within period study participation Breast feeding planning breast feed within period study participation Allergy Candida antigen History severe asthma require emergency room visit hospitalization Current use betablocker medication ( may respond epinephrine case anaphylaxis ) History invasive squamous cell carcinoma cervix History receive PepCan If opinion Principal Investigator Investigators , best interest patient enter study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HSIL , CIN II/III</keyword>
</DOC>